NCT03316521View on ClinicalTrials.gov

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Complement Mediated Diseases
Interventions
DRUG

AMY-101

AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.

Trial Locations (1)

27265

HighPoint Clinical Trials Center, High Point

Sponsors
All Listed Sponsors
lead

Amyndas Pharmaceuticals S.A.

INDUSTRY

NCT03316521 - First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter